Legacy Capital Group California Inc. Raises Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Legacy Capital Group California Inc. grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 20.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,229 shares of the biopharmaceutical company’s stock after purchasing an additional 3,900 shares during the quarter. Legacy Capital Group California Inc.’s holdings in Amicus Therapeutics were worth $219,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. OLD Second National Bank of Aurora purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at approximately $26,000. Hazlett Burt & Watson Inc. raised its stake in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares in the last quarter. Blue Trust Inc. lifted its holdings in Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new position in shares of Amicus Therapeutics in the 3rd quarter valued at about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter worth about $55,000.

Amicus Therapeutics Stock Up 1.3 %

FOLD stock opened at $9.19 on Friday. The company has a 50 day moving average price of $9.56 and a two-hundred day moving average price of $10.41. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The stock has a market capitalization of $2.75 billion, a P/E ratio of -51.06, a PEG ratio of 1.60 and a beta of 0.61. Amicus Therapeutics, Inc. has a one year low of $8.78 and a one year high of $14.02.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Wells Fargo & Company cut their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. increased their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Guggenheim lifted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Amicus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $16.75.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.